
|Videos|May 25, 2022
Clinical Pearls on Tailoring Dosing Strategies in Metastatic Kidney Cancer
David Aggen, MD, PhD, identifies dosing strategies that may maximize treatment efficacy while minimizing toxicity in patients with kidney cancer.
Advertisement
Episodes in this series

Advertisement
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves RP1/Nivolumab for Progression on Anti–PD-1 Therapy in Melanoma
2
The Lowest-Ever Hazard Ratio in Multiple Myeloma Bispecific Trials?
3
Why Earlier CAR T-Cell Therapy May Benefit Patients With Multiple Myeloma
4
Developers Initiate Phase 2/3 Ivonescimab/EV Trial in Bladder Cancer
5






























































